genXone SA
5.90
PLN
0.00
(0.00%)
genXone SA
NEWCONNECT:GX1
(NewConnect)
Recent
price
5.90
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- genXone SA is a biotechnology and molecular diagnostics company that specializes in next-generation genetic sequencing and molecular biology laboratory services. The company provides commercial and research-grade genomic solutions utilizing long-read nanopore sequencing technologies, serving clients across clinical healthcare, pharmaceutical research, biotechnology, agriculture, veterinary sciences, and food production. genXone SA operates primarily through two segments: Next-Generation Sequencing and Molecular Diagnostics. The company's product and service portfolio includes Whole Genome Sequencing for human, animal, plant, and microbial genomes; Shotgun Metagenomic and Targeted Metagenomic Sequencing for comprehensive microbial community profiling; Transcriptome, Epigenetic, and Plasmid DNA Sequencing; Custom Bioinformatic Data Analysis, pipeline construction, and genetic variant annotation; Real-Time Polymerase Chain Reaction diagnostic assays for the detection and quantification of viral, bacterial, fungal, and parasitic pathogens; NANOBIOME, a proprietary human gut microbiome profiling platform that evaluates intestinal bacterial biodiversity and provides functional health and nutritional insights; Specialized Direct-to-Consumer and Clinician Diagnostic Panels, covering tick-borne diseases, intimate infections, and respiratory pathogens; and Contract Research Laboratory Services supporting medical product evaluation, biomarker validation, and industrial biotechnology applications. In recent developments, genXone SA has expanded its specialized diagnostic portfolio through an international partnership with Danish genomics firm gMendel to deliver advanced molecular diagnostic solutions for genetic disorders, including spinal muscular atrophy, cystic fibrosis, Fragile X syndrome, and Klinefelter syndrome. The company has upgraded its laboratory infrastructure through the integration of modern high-throughput Oxford Nanopore Technologies platforms, such as the P2Solo sequencing system, and has incorporated artificial intelligence algorithms into its bioinformatic pipelines to optimize sequencing data interpretation. Furthermore, genXone SA launched expanded diagnostic testing panels for tick-borne pathogens, enhanced the analytical reporting framework and clinical guide resources for its flagship NANOBIOME platform, and secured renewed ISO 9001:2015 quality management certifications for its laboratory facilities. Originally established in 2015 and transformed into a joint-stock company in 2018, genXone SA is headquartered in Zlotniki, Poland, and is publicly traded on the Warsaw Stock Exchange NewConnect market under the ticker GX1.